The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy

After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID‐19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/B...

Descripción completa

Detalles Bibliográficos
Autor principal: Senn, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Special Issue Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350415/
https://www.ncbi.nlm.nih.gov/pubmed/35819115
http://dx.doi.org/10.1002/pst.2226
_version_ 1784762209627275264
author Senn, Stephen
author_facet Senn, Stephen
author_sort Senn, Stephen
collection PubMed
description After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID‐19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.
format Online
Article
Text
id pubmed-9350415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93504152022-08-04 The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy Senn, Stephen Pharm Stat Special Issue Papers After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID‐19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons. John Wiley & Sons, Inc. 2022-07-12 2022 /pmc/articles/PMC9350415/ /pubmed/35819115 http://dx.doi.org/10.1002/pst.2226 Text en © 2022 The Author. Pharmaceutical Statistics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Special Issue Papers
Senn, Stephen
The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title_full The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title_fullStr The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title_full_unstemmed The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title_short The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
title_sort design and analysis of vaccine trials for covid‐19 for the purpose of estimating efficacy
topic Special Issue Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350415/
https://www.ncbi.nlm.nih.gov/pubmed/35819115
http://dx.doi.org/10.1002/pst.2226
work_keys_str_mv AT sennstephen thedesignandanalysisofvaccinetrialsforcovid19forthepurposeofestimatingefficacy
AT sennstephen designandanalysisofvaccinetrialsforcovid19forthepurposeofestimatingefficacy

Ejemplares similares